

A phase I/II, partially randomised, open-labelled study of visilizumab in patients with severe ulcerative colitis refractory to intravenous corticosteroids

Submission date 08/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 20/02/2006	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 09/09/2008	Condition category Digestive System	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Daniel Hommes

Contact details

Academic Medical Center
Department of Gastroenterology
Room C2-330
Melbergdreef 9
Amsterdam
Netherlands
1105AZ
d.w.hommes@amc.uva.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

291-408

Study information

Scientific Title

Study objectives

To evaluate the safety and tolerability of visilizumab when administered to patients with severe ulcerative colitis (UC) that is refractory to intravenous steroids.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the local Medical Ethics Committee on 15th October 2003 (ref: 03 /220).

Study design

Partially randomised, open labelled study, phase I/II

Primary study design

Interventional

Secondary study design

Multi-centre

Study setting(s)

GP practice

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Ulcerative colitis

Interventions

In stage 1, patients were randomised to receive one of the following doses: 5.0 or 7.5 or 10.0 or 12.5 µg/kg. Due to amendment C (dated 06/05/2005) it was decided that in stage 2 all patients would receive 5.0 µg/kg. Visilizumab was administered intravenously on two consecutive daily doses.

Intervention Type

Drug

Phase

Phase I/II

Drug/device/biological/vaccine name(s)

Visilizumab

Primary outcome measure

To evaluate the safety of tolerability of visilizumab when administered to patients with severe UC that is refractory to IV steroids.

Secondary outcome measures

1. To obtain preliminary evidence of biological activity in this indication. This will be assessed by quantifying the number of patients who experience an improvement in disease symptoms (as indicated by a decrease in scores on Modified Truelove and Witts Severity Index [MTWSI] and a Mayo-Clinic system for assessing UC activities), and to avoid surgical intervention
2. To compare patients with and without detectable whole blood Epstein-Barr Virus (EBV) for the safety profiles of visilizumab
3. To determine the optimal clinical dose (OCD) of visilizumab in the study patient population
4. To determine relationships between pharmacokinetics and pharmacodynamics of visilizumab, laboratory immunologic parameters, clinical response and toxicity
5. To evaluate the safety and tolerability of a second course of treatment with visilizumab when administered to patients who responded to a first course, but subsequently relapsed

Overall study start date

01/07/2003

Completion date

31/01/2006

Eligibility**Key inclusion criteria**

1. 18 to 70 years of age
2. A diagnosis of UC verified by colonoscopy or barium enema performed within 36 months prior to study entry
3. For first time therapy with visilizumab, active disease documented by a Modified Truelove and Witts Severity Index (MTWSI) score of 11 to 21 despite a course of intravenous (IV) steroids that occurred within 60 days prior to study day one and lasted at least five days. Patients who undergo re-treatment with visilizumab must meet the same MTWSI score requirement but need not to have failed IV steroids before re-treatment
4. If patient is a male or female of reproductive potential, he or she must agree to use adequate contraception during the study and for three months after receiving visilizumab
5. For women of childbearing potential, a negative serum pregnancy test at baseline screening
6. Patients must have been tested negative for Clostridium difficile within 10 days prior to treatment with visilizumab
7. Patients who are capable of understanding the purpose and risks of the study and who provide a signed and dated informed consent. For US sites only, patients must also provide an authorisation to use protected health information.

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

144

Key exclusion criteria

1. Ulcerative colitis (UC) requiring immediate surgical, endoscopic, or radiologic interventions, including massive haemorrhage, perforation and sepsis, suppurative complications (intra-abdominal or perianal abscesses) or toxic megacolon
2. History of total proctocolectomy, or subtotal colectomy with ileorectal anastomosis
3. Presence of ileostomy
4. White blood cell count less than $2.5 \times 10^3/\mu\text{l}$, platelet count less than $150 \times 10^3/\mu\text{l}$, or haemoglobin less than 8 g/dl
5. Patients with serious infections, particularly those of viral etiology, e.g. active cytomegalovirus (CMV) colitis. This includes any incidence of opportunistic infections within the past year.
6. Patients who have received a live vaccine within six weeks prior to study entry (patients may not receive a live vaccine during treatment or for six weeks after treatment with visilizumab)
7. Patients with a history of thrombophlebitis or pulmonary embolus
8. Significant organ dysfunction including: cardiac, renal, liver, central nervous system, pulmonary, vascular, gastrointestinal endocrine or metabolic dysfunction (e.g. creatinine greater than 1.6 mg/dl, or alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase greater than 1.5 x upper limit of normal) or history of coronary artery disease within six months prior to study entry
9. Patients with a history of lymphoproliferative disorder (LPD) or malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix that has been adequately treated
10. Pregnant women or nursing mothers
11. Seropositive for infection with human immunodeficiency virus-1 (HIV-1), hepatitis B virus (HBV) surface antigen, or hepatitis C virus (HCV) antibody
12. An Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA) load greater than 5000 copies/ml in stage 1 and greater than 30,000 copies/ml in stage 2
13. Treatment with any investigational drugs or therapies within 60 days prior to study entry
14. Treatment with an antibody therapy within 60 days prior to study entry
15. Treatment with cyclosporine or tacrolimus (FK506) within three months prior to study entry
16. All of the following: a history of seizures, a history of both chronic and current treatment with anticonvulsant medication, and no documentation of therapeutic blood levels of anticonvulsant medication within seven days before study enrolment

Date of first enrolment

01/07/2003

Date of final enrolment

31/01/2006

Locations

Countries of recruitment

Austria

Belgium

Bulgaria

Canada

Germany

Netherlands

United States of America

Study participating centre

Academic Medical Center

Amsterdam

Netherlands

1105AZ

Sponsor information**Organisation**

PDL BioPharma Inc. (USA)

Sponsor details

34801 Campus Drive

Fremont

United States of America

94587

mdyer@pdl.com

Sponsor type

Industry

Website

<http://www.pdl.com/>

ROR

<https://ror.org/03ya6pd97>

Funder(s)

Funder type

Industry

Funder Name

PDL BioPharma Inc. (USA)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration